Biggest News Aggregation in the World
📰 Resented News

Page 29 - Resented News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Resented. Real-time updates on events, politics, business and more.

Precigen, Inc. Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference

Precigen, Inc. presented pipeline and corporate updates at the 41st Annual J.P. Morgan Healthcare Conference. PRGN-2012 AdenoVerse™ Immunotherapy in RRP. Overview: PRGN-2012 is an investigational... | January 12, 2023
United States Mayo Clinic In Rochester Helen Sabzevari Clintt Allen American Society Of Hematology Cancer Research

USPA Global Licensing Inc. (847158): Global Polo Entertainment Extends Historic Agreement With ESPN Through 2024 to Broaden Access to the Action-Packed Sport of Polo, Presented by U.S. Polo Assn.

WEST PALM BEACH, Fla., Jan. 10, 2023, the official brand of the United States Polo Association (USPA), the governing body for the sport of polo in the United States. The original agreement, signed
New Zealand General New Zealand United States Shannon Stilson Kostenloser Wertpapierhandel Stewart Armstrong

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

REGiMMUNE Limited: REGiMMUNE Presented Positive Results of RGI-2001 in the Reduction of Acute GvHD from Phase 2b Study at the 2022 ASH Annual Meeting

RGI-2001 was well tolerated and associated with a meaningful reduction in the incidence of severe acute GvHD REGiMMUNE Limited, a clinical-stage biopharmaceutical company developing innovative
United States Bin Chen Kostenloser Wertpapierhandel Kenzo Kosuda Charlie Hsu American Society Of Hematology

F. Hoffmann-La Roche Ltd: Interim data from phase III study presented at ASH 2022 show Hemlibra achieved meaningful bleed control in infants from birth

The HAVEN 7 study was designed to further confirm the benefit of preventative treatment (prophylaxis) with Hemlibra from birth in previously untreated or minimally treated infants with severe haemophilia
United States United Kingdom Levi Garraway Mabthera Rituxan Gazyva Gazyvaro Sabine Borngr

Tessa Therapeutics Ltd: Tessa Therapeutics Announces New Clinical Data from Phase 1 Allogeneic Study Presented at 2022 Annual Meeting of American Society of Hematology (ASH)

Oral podium presentation highlights data demonstrating a 79% overall response rate and complete responses in 43% of relapsed or refractory CD30-positive lymphomas treated with Tessa's "off the shelf" CD30.CAR
United States Baylor College Of Medicine Kostenloser Wertpapierhandel Ivan Horak Davidh Quach Dave Schemelia

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science